**DRAFT** August 14, 2014

## ADVISORY COMMISSION ON CHILDHOOD VACCINES (ACCV)

Parklawn Building, 5600 Fishers Lane, Rockville, Maryland Conference Room 10-65

September 04 & 05, 2014

(1:00pm – 4:25 pm Eastern Daylight Time) (9:00 am – 1:15 pm Eastern Daylight Time)

Dial: 1-877-917-4913 Passcode: ACCV

Time	Agenda Item	Presenter	
1:00 PM	Welcome and Chair Report	Mr. David King, Chair	
1:10 PM	Welcome	Ms. Cheryl Dammons Associate Administrator, HRSA	
1:15 PM	Public Comment on Agenda Items	71550ciate 71diffinistrator, 111071	
1:20 PM	Approval of June 2014 Minutes	Mr. David King, Chair	
1:25 PM	Report from the Division of Vaccine Injury Compensation	Dr. A. Melissa Houston Acting Director, DVIC	
1:55 PM	Clarification on Proposed Changes to the Vaccine Injury Table	Dr. A. Melissa Houston Acting Director, DVIC	
2:55 PM	Report from the Department of Justice	Mr. Vince Matanoski, Deputy Director, Torts Branch, DOJ	
3:25 PM	VICP Outreach Plan		
4:25 PM	Public Comment (follows the preceding topic and may commence earlier or later than 4:25 pm)		
4:40 PM	Adjournment of the 1 <sup>st</sup> Day of the ACCV Quarterly Meeting		

Friday	September 05,	2014
ime	Agend	la Iter

Time	Agenda Item	Presenter
9:00 AM	Welcome & Unfinished Business from Day 1	Mr. David King, Chair
9:15 AM	Report from the Process Workgroup	Ms. Luisita dela Rosa, ACCV Member
10:00 AM	Update on the Immunization Safety Office (ISO), Centers for Disease Control and Prevention (CDC) Vaccine Activities	Dr. Tom Shimabukuro CDC
10:15 AM	Discussion of Proposed Revisions to VAERS Form (2.0)	Dr. Tom Shimabukuro CDC
11:15 AM	Pneumococcal Polysaccharide (Pneumovax 23) Vaccine Safety Presentation	Ms. Elaine Miller, R.N., MPH CDC
11:45 AM	Zoster (Shingles) Vaccine Safety Presentation	Ms. Elaine Miller, R.N., MPH CDC
12:15 PM	Update on the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) Vaccine Activities	Dr. Barbara Mulach NIAID, NIH
12:45 PM	Update on the Center for Biologics, Evaluation and Research (CBER), Food and Drug Administration (FDA) Vaccine Activities	Ms. Valerie Marshall, Ph.D CBER, FDA
1:00 PM	Update from the National Vaccine Program Office (NVPO)	Dr. Karin Bok, NVPO
1:15 PM	Public Comment (follows the preceding topic and may commence earlier or later than 1:15 pm)	Mr. David King, Chair
1:30 PM	Future Agenda Items/New Business	Mr. David King, Chair
1:45 PM	Adjournment of the ACCV Quarterly Meeting	